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Background: Transient ischemic attack (TIA) and minor stroke (TIAMS) are risk
factors for stroke recurrence. Some TIAMS may be preventable by appropriate
primary prevention. We aimed to recruit “possible-TIAMS” patients in the INternational
comparison of Systems of care and patient outcomes In minor Stroke and TIA
(INSIST) study.
Methods: A prospective inception cohort study performed across 16 Hunter–Manning
region, Australia, general practices in the catchment of one secondary-care acute
neurovascular clinic. Possible-TIAMS patients were recruited from August 2012 to
August 2016. We describe the baseline demographics, risk factors and pre-event
medications of participating patients.
Results: There were 613 participants (mean age; 69 ± 12 years, 335 women), and 604
(99%) were Caucasian. Hypertension was the most common risk factor (69%) followed
by hyperlipidemia (52%), diabetes mellitus (17%), atrial fibrillation (AF) (17%), prior TIA
(13%) or stroke (10%). Eighty-nine (36%) of the 249 participants taking antiplatelet
therapy had no known history of cardiovascular morbidity. Of 102 participants with
known AF, 91 (89%) had a CHA2DS2-VASc score ≥ 2 but only 47 (46%) were taking
anticoagulation therapy. Among 304 participants taking an antiplatelet or anticoagulant
agent, 30 (10%) had stopped taking these in the month prior to the index event.
Tomari et al. Minor Stroke and Stroke-Mimic Syndrome
Conclusion: This study provides the first contemporary data on TIAMS or TIAMS-
mimics in Australia. Community and health provider education is required to address the
under-use of anticoagulation therapy in patients with known AF, possibly inappropriate
use of antiplatelet therapy and possibly inappropriate discontinuation of antiplatelet or
anticoagulation therapy.
Keywords: transient ischemic attack, minor stroke, stroke-mimic syndrome, atrial fibrillation, anticoagulation
therapy
INTRODUCTION
Transient ischemic attack and minor stroke (TIAMS) account
for ∼40% of all cerebral ischemic events (1, 2) and can precede
a disabling or fatal stroke (3) and major cardiovascular events
(4, 5). Recurrent stroke usually occurs very early after TIAMS (6)
and rapid specialist assessment and intervention has been shown
to reduce this risk (7, 8). Therefore, a rapid response within
the system of care is required to initiate secondary prevention
strategies (4, 8). Current evidence-based guidelines include
recommendation for rapid treatment and/or rapid specialist
referral (9). Clinical diagnosis of TIAMS is often challenging and
it can be difficult to distinguish TIAMS from benign, low risk
“stroke-mimic” syndromes (10, 11). Further, it is uncertain how
compliant primary health care practitioners are with guidelines
directed at the management of TIAMS and how applicable the
guidelines are in primary care settings.
In the INternational comparison of Systems of care and
patient outcomes In minor Stroke and Tia (INSIST) study (12),
we recruited “possible-TIAMS” patients presenting to primary
and secondary care settings. The aim of this study was to describe
baseline patient characteristics, outcomes and systems of care of
all patients enrolled into the INSIST study.
METHODS
The rationale and methods of the INSIST study have been
previously reported (12). Patients were recruited from theHunter
and Manning valley regions of New South Wales, within the
referral territory of the Acute Neurovascular Clinic (ANVC) at
the JohnHunter Hospital between August 2012 and August 2016.
The John Hunter Hospital is the major teaching and referral
hospital of the Hunter New England Local Health District.
Patients attended one of 16 general practices (11 urban and 5
rural practices including 2 where general practitioners (GPs)
staff the local hospitals) within the geographic footprint of the
Hunter New England andCentral Coast PrimaryHealthNetwork
(HNECCPHN) (Figure 1). The estimated population within the
HNECCPHN region is 1,200,000 of whom 18.3% are aged 65+
years (compared to 14.4% nationally) and 18.5% have circulatory
system disease (17.3% prevalence nationally) (13).
In this study, TIAMS was ascertained using multiple
overlapping methods; primarily general practice records but
also from hospital emergency departments, after-hours GP
services, hospital inpatient admissions and discharges and ANVC
attendance at John Hunter Hospital (12). All patients with
a possible diagnosis of TIAMS were invited to participate.
Episodes with symptoms lasting <24 h were classified as TIAs,
and prolonged (>24 h) episodes with National Institute of
Health Stroke Scale < 5 at presentation were classified as
minor strokes. Patients with both (i) symptoms lasting more
than 24 h and (ii) National Institute of Health Stroke Scale
>5 at presentation, were excluded. Information recorded at the
baseline interview included demographics (age, sex, ethnicity,
residence, marital status, education, pre-event employment
status, recent occupation, socioeconomic status of area residence
[Socio-Economic Index for Area, Index of Relative Socio-
economic Disadvantage [SEIFA IRSD] (14)], lifestyle factors
(smoking status, alcohol consumption, exercise hours), past
medical history and pre-event medications. Further data was
obtained from participants’ clinical notes.
RESULTS
During this study, there were 1,363 patients where TIAMS
was considered a possible diagnosis whereby 643 consented to
participate (response rate 47%), and 613 (335 women; mean
[SD] age, 69.8 [12.0] years) completed the baseline interview.
Among 613 participants, 298 were adjudicated as TIAMS of
whom 175 (29%) had TIA and 123 (20%) had minor stroke.
Prior to the index event, 550 (90%) participants were functionally
independent (Modified Rankin Scale 0–2).
Participants were somewhat older (on average, by 3 years), and
more frequently had focal neurological symptoms, compared to
non-participants (Supplemental Material). Most patients were
represented across three age bands; 65–74 years (209, 34%),
75–84 years (182, 30%) and 55–64 years (106, 17%) (Table 1).
Almost all the participants (604, 99%) were Caucasian. There
were differences between male and female participants in marital
status and living arrangements with women more likely to be
widowed (77, 23% of women vs. 28, 10% of men), living alone
(100, 30% vs. 48, 17%) and living in rental accommodation (39, 12
vs. 24, 9%) (Table 2). Education status was divided into more or
less than 10 years of schooling with 365 (60%) having education
beyond 10 years (Table 3). Attainment of high school certificate
was the most common education level of men (92, 33%) and
women (81, 24%). Most of the participants (433, 71%) were
retired (330, 54% on a government pension and 103, 17% on
a self-funded retirement) and 136, 22% were working (70, 11%
in full time and 66, 11% in part time/casual employment). The
distribution of socioeconomic status of area (SEIFA IRSD—an
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FIGURE 1 | Locations of participating general practices in the Hunter New England and Central Coast Primary Health Network (HNECCPHN) region.
TABLE 1 | Age and sex structure of the study populations.
Age band Total n, (%) Men n, (%) Women n, (%)
<45 19 (3.1) 3 (1.0) 16 (4.8)
45–54 44 (7.2) 19 (6.8) 25 (7.5)
55–64 106 (17) 51 (18) 55 (16)
65–74 209 (34) 106 (38) 103 (31)
75–84 182 (30) 73 (26) 109 (33)
≥85 53 (8.6) 26 (9.4) 27 (8.1)
Total 613 278 335
area-based weightedmeasure of social and economic resources of
people and household, expressed as a decile) is shown in Figure 2.
In terms of vascular risk factors, 326 (53%) had never smoked
tobacco, 251 (41%) were ex-smokers and 36 (5.9%) were current
smokers (Table 4). The median age at which the ex-smokers
stopped was 40 years for both men and women. Alcohol intake
ranged from 0 standard drink equivalents per week in 42%
(79, 28% men and 180, 54% women), to 1–5 standard drink
equivalents per week in 24% (61, 22% men and 88, 26% women).
Ten percent of the population reported no exercise (22, 8% men
and 42, 13% women).
Hypertension was the most common (425, 69%) risk factor,
followed by hyperlipidemia (321, 52%), diabetes mellitus (106,
17%), atrial fibrillation (AF) (102, 17%), previous TIA (78, 13%)
and previous stroke (64, 10%) (Table 5). At the time of the
possible TIAMS, 249 (40%) participants were taking antiplatelet
therapy (215, 35% single and 34, 5.5% dual antiplatelet therapy)
with aspirin being the most common single agent (176, 29% of all
participants) (Table 6).
Two hundred and thirty-one participants (38%) had at
least one known cardiovascular morbidity (stroke, transient
ischemic attack, angina, myocardial infarction, coronary artery
bypass grafting or angioplasty, carotid endarterectomy and
peripheral vascular disease) at the time of the event, of
whom 158 (68%) were taking an antiplatelet agent, 33
(14%) were taking an anticoagulation agent, including 28
with AF. 89 (36%) of the 249 people taking antiplatelet
therapy had no known history of cardiovascular morbidity.
Among these 89 patients, 19 (21%) had a history of “funny
turn” (funny turn is not a specific diagnosis and potentially
includes neurological, cardiovascular, metabolic, vestibular and
psychological condition), 7 (7.9%) had an AF history and
5 (5.6%) had both history of a funny turn and AF. Of
these 12 participants with AF, six had a CHA2DS2-VASc
score ≥2.
We found that 56 of 613 (9.1%) participants were taking
an anticoagulant agent at the time of the event, 45 (7.3%)
warfarin and 11 (1.8%) a non-vitamin K antagonist oral
anticoagulant (NOAC). In patients with a known diagnosis
of AF, 47 (46%) were taking an anticoagulant despite 91
(89%) having a CHA2DS2-VASc score ≥ 2. Among 304
participants taking an antiplatelet or anticoagulant agent,
30 (10%) had stopped taking in the month prior to the
index event. Anti-platelet or anti-coagulant medications
were stopped in preparation for an invasive procedure
in 14 (47%), by the participant on their own volition
in 9 (30%), because the participant forgot to take the
medication in 4 (13%), and because of bleeding in 1
(3.3%). 227 (37%) participants were taking a statin (11% at
recommended maximum dose) and 394 (64%) were taking
antihypertensive agents.
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TABLE 2 | Ethnicity, residence, housemate, and marital status in enrolled patients.
Total,
N = 613, (%)
Men,
N = 278, (%)
Women,
N = 335, (%)
Ethnicity
Caucasian 604 (99) 273 (98) 331 (99)
Australian 496 (81) 222 (80) 274 (82)
British & Irish 69 (11) 32 (12) 37 (11)
Southern & Eastern European 17 (2.8) 6 (2.1) 11 (3.2)
Northern & Western European 11 (1.7) 9 (3.2) 2 (0.6)
New Zealander 8 (1.3) 3 (1.1) 5 (1.5)
American 3 (0.5) 1 (0.4) 2 (0.6)
Sub-Saharan Africa 2 (0.3) 2 (0.7) 0
Aboriginal 2 (0.3) 1 (0.4) 1 (0.3)
Maori 1 (0.2) 1 (0.4) 0
Polynesian 1 (0.2) 1 (0.4) 0
South East Asian 1 (0.2) 0 1 (0.3)
Southern & Central Asian 1 (0.2) 0 1 (0.3)
North African & Middle Eastern 1 (0.2) 1 (0.4) 0
Residence
Own home 495 (81) 230 (83) 265 (79)
Rented 63 (10) 24 (8.6) 39 (12)
Retirement village or similar 45 (7.3) 20 (7.2) 25 (7.5)
Others 10 (1.6) 4 (1.4) 6 (1.8)
Living with
Partner or family 457 (75) 228 (82) 229 (68)
Alone 148 (24) 48 (17) 100 (30)
Others 8 (1.3) 2 (0.7) 6 (1.8)
Marital
Married/Partner/Defacto 427 (70) 223 (80) 204 (61)
Widowed 105 (17) 28 (10) 77 (23)
Seperated/Divorced 44 (7.1) 16 (6.0) 28 (8.4)
Single 37 (6.0) 11 (4.0) 26 (7.8)
TIA, transient ischemic attack.
DISCUSSION
The diagnosis of TIAMS and its management are complex,
This study provides a comprehensive and contemporary
description of “possible-TIAMS” patients who have engaged with
medical care.
Generalizability of Findings—Ethnicity and
Socioeconomic Status
All but nine participants were Caucasian, which is in stark
contrast to the situation in Auckland, New Zealand where 78%
of TIA patients were of European origin, 11% Maori/Pacific
and 10% Asian/Other (15). In our study region, 48,002 (4.2%)
identify as Aboriginal and/or Torres Strait Islanders (compared
to 2.5% nationally) and a lower proportion of people reported
being from non-English speaking backgrounds (4.5% compared
to 15.7% nationally) (13). Aboriginal and Torres Strait Islander
people have a three-fold greater risk of cerebrovascular diseases,
TABLE 3 | Education, pre-event employment and recent occupation in enrolled
patients.
Total,
N = 613, (%)
Men,
N = 278, (%)
Women,
N = 335, (%)
Education
Schooling <10 years 248 (40) 84 (30) 164 (49)
more than 10 years 365 (60) 194 (70) 171 (51)
Postgraduate degree 28 (4.6) 19 (6.8) 9 (2.7)
Graduate Certificate or Diploma 14 (2.3) 6 (2.2) 8 (2.4)
Bachelor Degree 56 (9.1) 29 (10) 27 (8.1)
Advanced Diploma & Diploma 62 (10) 31 (11) 31 (9.3)
Certificate level 173 (28) 92 (33) 81 (24)
School yr 11 and 12 32 (5.2) 17 (6.1) 15 (4.5)
Pre-event employment status
Retired 433 (71) 198 (71) 235 (75)
On government pension 330 (54) 138 (50) 192 (57)
Self-funded 103 (17) 60 (22) 43 (13)
Working 136 (22) 64 (23) 72 (23)
Full time 70 (11) 44 (16) 26 (7.8)
Part time/casual 66 (11) 20 (7.2) 46 (14)
Unable to work and on pension 22 (3.6) 12 (4.3) 10 (3.0)
Others 22 (3.6) 4 (1.4) 18 (5.7)
Recent occupation
Clerical and Administrator 103 (17) 17 (6.1) 86 (26)
Managerial 96 (16) 75 (27) 21 (6.3)
Professional 95 (15) 46 (17) 49 (15)
Laborers 67 (11) 26 (9.4) 41 (12)
Community Personal Service 59 (10) 11 (4.0) 48 (14)
Technicians trades 55 (9.0) 50 (18) 5 (1.5)
Sales 51 (8.3) 9 (3.2) 42 (13)
Machinery operator and drivers 43 (7.0) 37 (13) 6 (1.8)
Others 44 (7.2) 7 (2.5) 37 (12)
Carer prior to the index event 67 (11) 20 (7.2) 47 (14)
and two-fold neurological conditions risk, compared to non-
Indigenous Australians (16). The low proportion of Aboriginal
or Torres Strait Islander participants may reflect the fact that
none of the Aboriginal Medical Services in the region (where
an appreciable proportion of the Aboriginal and Torres Strait
Islander community access health care) elected to participate in
the study. It is also possible that our findings reflect lower rates
of presenting to primary or secondary care with neurological
symptoms in this group.
Our study population was of relatively lower socioeconomic
status compared to the distribution in the HNECCPHN
population (IRSD decile 6 was the most common (42%) followed
by decile 7 (32%) reported from the Australian Census 2016)
(14). The proportion of participants in each SEIFA IRSD
decile declining as socio-economic status decile increased. Low
socioeconomic status has been associated with fatal stroke and
non-fatal stroke incidence (17). Education is one of the many
constituent measures included in the SEIFA– IRSD and we note
that 40% of our study population had <10 years of education.
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FIGURE 2 | Index of Relative Socio-economic Disadvantage. This index is a
general socio-economic index that summarizes a wide range of information
about the economic and social resources of people and households within an
area. Because this index focuses on disadvantage, only measures of relative
disadvantage are included. This means that a high score reflects a relative lack
of disadvantage rather than relative advantage.







Exercise, hours per week 4 [2–8] 5.5 [3–10] 4 [2–7]
Alcohol, standard drink equivalent per week 1.6 [0–8.9] 5.6 [0–15] 0 [0–4]
Smoking status
Never 326 (53) 111 (40) 215 (64)
Ex 251 (47) 149 (54) 102 (30)
Current 36 (5.9) 18 (6.7) 18 (5.4)
Per day smokes
Current 16 [10–23] 18 [10–24] 15 [10–20]
Ex 15 [5–20] 20 [10–20] 10 [4.3–20]
Smoking years
Current 44 [34–53] 40 [30–45] 48 [40–58]
Ex 20 [10–40] 17 [10–30] 17 [6.3–30]
Age stopped smoking (Ex) 40 [29–60] 40 [27–50] 40 [28–55]
Stopped last 12M, % of Ex 8 (3.2) 3 (2.0) 5 (5.0)
Data are presented as median [interquartile range] or absolute (percentage) values.
Baseline Antiplatelet and Anticoagulation
Status
About one third of patients were taking antiplatelet therapy
(38%) prior to the index event. This likely reflects the prior
history of vascular disease. However, many of the participants
were taking antiplatelet agents without an apparent indication.
This finding of possible inappropriate prescription of antiplatelet
agents is consistent with previous studies (18, 19). Anticoagulant
therapy was underused considering the CHA2DS2-VASc score
in the study population, with 46% of participants with a known
diagnosis of AF treated (20). This is consistent with findings
of previous studies where 23–30% of TIA patients with known
TABLE 5 | Past medical histories in enrolled patients.
Total,
N = 613, (%)
Men,
N = 278, (%)
Women,
N = 335, (%)
Previous stroke 64 (10) 32 (12) 32 (9.6)
Previous TIA 78 (13) 48 (17) 30 (9.0)
Previous funny turn* 149 (24) 55 (20) 94 (28)
Hypertension 425 (69) 197 (71) 228 (68)
Diabetes mellitus 106 (17) 60 (22) 46 (14)
Hyperlipidemia 321 (52) 135 (49) 186 (56)
Atrial fibrillation 102 (17) 52 (19) 50 (15)
Angina 101 (16) 58 (21) 43 (13)
Previous myocardial infarction 73 (12) 43 (15) 30 (9.0)
Heart failure 51 (8.3) 20 (7.2) 31 (9.3)
CABG or Angioplasty 71 (12) 50 (18) 21 (6.3)
Carotid endarterectomy 17 (2.8) 15 (5.4) 2 (0.6)
Peripheral vascular disease 40 (6.5) 28 (10) 12 (3.6)
Cancer 125 (20) 65 (23) 60 (18)
Migraine 200 (33) 52 (19) 148 (44)
Epilepsy 16 (2.6) 9 (3.2) 7 (2.1)
*Funny turn is a non-specific diagnosis (potentially includes neurological, cardiovascular,
metabolic, vestibular, and psychological conditions).
CABG, coronary artery bypass grafting; TIA, transient ischemic attack.
TABLE 6 | Pre-event medications in enrolled patients.
Total,
N = 613, (%)
Men,
N = 278, (%)
Women,
N = 335, (%)
Antiplatelet 249 (40) 130 (47) 119 (36)
Single 215 (35) 109 (39) 106 (32)
Aspirin 176 (29) 93 (33) 83 (25)
Clopidogrel 39 (6.3) 16 (5.8) 23 (6.9)
Dual 34 (5.5) 21 (7.6) 13 (3.9)
Aspirin + Clopidogrel 17 (2.8) 10 (3.6) 7 (2.1)
Aspirin + Dipyridamole 17 (2.8) 11 (4.0) 6 (1.8)
Anticoagulant 56 (9.1) 22 (7.9) 34 (10)
Warfarin 45 (7.3) 17 (6.1) 28 (8.4)
NOAC 11 (1.8) 5 (1.8) 6 (1.8)
Stopped antiplatelet or anticoagulant* 30 (4.9) 23 (8.3) 7 (2.1)
Statin 227 (37) 106 (38) 121 (36)
Maximum dose 25 (4.4) 16 (5.8) 9 (2.7)
Antihypertensive drug 394 (64) 184 (66) 210 (63)
*Stopped in a month prior to the index event.
NOAC, non-vitamin K antagonist oral anticoagulants.
AF were taking anticoagulation therapy at the time of the TIA
(15, 21, 22).
This study provides evidence of a clear need for optimization
of antiplatelet and anticoagulation therapy in patients with
established vascular disease and AF. In particular, GPs should
be encouraged to calculate CHA2DS2-VASc scores and consider
the need for anticoagulation in patients presenting with AF.
Presentation with possible-TIAMS provides a key opportunity
to start anticoagulantion therapy if appropriate based on risk
stratification and bleeding risk. The finding that antiplatelet or
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anticoagulation therapy had been stopped in the month prior to
the index event in many patients is also a cause for concern. This
highlights a need for GPs to carefully consider the potential risks
and benefits when considering cessation of anticoagulation or
antiplatelet therapy, and the need to promptly reinstitute therapy
as soon as it is safe after temporary discontinuation.
Statin and Antihypertensive Preventive
Treatment
The prevalence of statin (37%) and antihypertensive therapy
(64%) used in the study population seems modest given
prevalence of known hyperlipidaemia (52%) and hypertension
(69%), as well as the prevalence of diabetes mellitus (17%) and
previous stroke (13%). In an absolute cardiovascular risk (ACVR)
analysis of a subgroup participating early in the INSIST study,
72% of participants in which ACVR could be calculated had
high or moderate ACVR (23). Considering this risk proportion,
the prevalence of statin and antihypertensive therapy seems
relatively modest.
Strengths and Limitations
This study has a number of strengths. It is a comprehensive
community-based study of TIAMS patients engaging with
health systems at any level that used multiple overlapping case
ascertainment methods for possible TIAMS. The study also
has a number of limitations. There was a modest response
or consent rate of 47%. This rate is typical of declining
response rates for cohort studies (24). We did not record a
past history of hemorrhage or other potential contraindications
to anti-thrombotic therapy. The study was performed at a
time when non-vitamin K antagonist oral anticoagulants were
still relatively new with subsequent rapid uptake of these
medicines and corresponding reductions in the use of warfarin
(25, 26). There was a lack of representation of the Aboriginal
and Torres Strait Islander community and lower number of
culturally and linguistically diverse individuals than would be
expected, reflecting the recruitment catchment demographics.
We are therefore unable to generalize the findings to non-
Caucasian populations.
CONCLUSIONS
This study provides the first contemporary data on TIAMS or
TIAMS-mimics in Australia. Worryingly, we found under-use
of anticoagulation therapy in patients with known AF prior to
the index event and possibly inappropriate use of antiplatelet
therapy. Community and health provider education is required
to address the under-use of anticoagulation therapy in patients
and possibly inappropriate discontinuation of antiplatelet or
anticoagulation therapy.
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